HCW Biologics

HCW Biologics Inc. is a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases. The firm considers age-related low-grade chronic inflammation as a contributing factor to several chronic diseases and conditions, such as cancer, cardiovascular disease, diabetes, neurodegenerative diseases, and autoimmune diseases. The company was founded by Hing C. Wong on April 2, 2018 and is headquartered in Miramar, FL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MIRAMAR, Fla., Aug. 12, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2022.

HCW Biologics Reports Second Quarter 2022 Financial Results And Recent Business Highlights

Issued Claims for Single-Chain Chimeric Polypeptide and Composition Claims for Lead Product Candidate, HCW9302 Issued Claims for Single-Chain Chimeric Polypeptide and Composition Claims for Lead Product Candidate, HCW9302

U.S. Patent Issued to HCW Biologics for Foundational Platform Technology

MIRAMAR, Fla., May 23, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases, announced today that Hing C. Wong, Ph.D., Founder and CEO of HCW Biologics, will give a corporate presentation on May 25, 2022 at the H.C. Wainwright Annual Global Life Sciences Conference.

HCW Biologics to Participate in H.C. Wainwright Annual Global Life Sciences Conference May 23 – 25, 2022

MIRAMAR, Fla., May 13, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2022.

HCW Biologics Reports First Quarter 2022 Financial Results and Recent Business Highlights

Cytokine-Based Fusion Proteins to Activate and Expand Memory-Like NK Cells  Without Using Feeder Cells Sufficient for Off-the-Shelf Multi-Dose Adoptive Cell Therapy

HCW Biologics to Showcase Two Novel Groups of Fusion Molecules Created with Proprietary and Versatile TOBI™ Platform At the 105th Annual Meeting of the American Association of Immunologists

Preclinical data for lead investigational drug, HCW9218,  in treatment of therapy-induced senescence in cancer

HCW Biologics' CEO Hing C. Wong, Ph.D.

$56 Million IPO Completed in July 2021 Expected to Fund Operating Expenses through 2023

HCW Biologics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights for 2021

Founder and CEO, Hing C. Wong, Ph.D., to be guest at “Fireside Chat” Founder and CEO, Hing C. Wong, Ph.D., to be guest at “Fireside Chat”

HCW Biologics to Present at 2022 Virtual Growth Conference Sponsored by the Maxim Group and M-Vest

The FDA cleared the Masonic Cancer Center, University of Minnesota to evaluate HCW Biologics Inc's (NASDAQ: HCWB) lead drug candidate, HCW9218, in Phase 1 trial in patients with advanced solid tumors with progressive disease after prior chemotherapies.

Masonic Cancer Center To Evaluate HCW Biologics' Bifunctional Fusion Protein In Advanced Cancers

UM cleared to proceed with clinical trial to evaluate HCW9218 in various advanced solid tumors, such as breast, ovarian, prostate, and colorectal cancers UM cleared to proceed with clinical trial to evaluate HCW9218 in various advanced solid tumors, such as breast, ovarian, prostate, and colorectal cancers

Masonic Cancer Center at the University of Minnesota Receives FDA Clearance to Proceed with Phase 1 Clinical Trial in Solid Tumors for HCW9218, HCW Biologics' Novel Bifunctional Fusion Protein

HCW Biologics Inc (NASDAQ: HCWB) has announced the publication of a scientific paper in Molecular Therapy highlighting preclinical data of its lead program, HCW9218. The preclinical data demonstrated that HCW9218 enhanced the anti-tumor efficacy of chemotherapy drugs and diminished their harmful side effects by reducing therapy-induced senescence (TIS).

HCW Biologics Lead Candidate Shows Preclinical Anti-Tumor Activity, Reduced Side Effects of Chemo

Preclinical Data for HCW 9218 Included in Pivotal Scientific Paper Published in Molecular Therapy Preclinical Data for HCW 9218 Included in Pivotal Scientific Paper Published in Molecular Therapy

HCW Biologics Inc. Announces its Lead Product Candidate Shown to Augment Anti-Tumor Activity and Reduce Side Effects of Chemotherapy Regimens

A Novel Platform to Create Multi-Functional Immunotherapeutics for Cancer Will Feature TOBI™ Discovery Platform and Lead Product Candidate, HCW9218 A Novel Platform to Create Multi-Functional Immunotherapeutics for Cancer Will Feature TOBI™ Discovery Platform and Lead Product Candidate, HCW9218

HCW Biologics' Founder and CEO Dr. Hing C. Wong Participating in Cambridge Healthtech Institute's Annual PepTalk Conference 2022

MIRAMAR, Fla., Jan. 06, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases, announced today that members of the HCW Biologics management team will participate in the H.C. Wainwright BioConnect Conference. The event is taking place January 10 – 13, 2022.

HCW Biologics to Participate in H.C. Wainwright BioConnect Conference January 10 – 13, 2022

Award recognizes extraordinary contributions to the growth of life sciences Award recognizes extraordinary contributions to the growth of life sciences

HCW Biologics' Founder and CEO Dr. Hing C. Wong Named Weaver H.

MIRAMAR, Fla., Nov. 12, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), an innovative biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported recent business highlights and financial results for its third quarter ended September 30, 2021.

HCW Biologics Reports Third Quarter Financial Results and Recent Business Highlights

Globalstar

Exela Technologies

Are these penny stocks worth buying right now? The post Good Penny Stocks to Buy Right Now?

Good Penny Stocks to Buy Right Now? 3 to Watch in November

HCW Biologics (HCWB) stock is rocketing higher on Thursday thanks to a recent update from the U.S. Food and Drug Administration (FDA). The post HCWB Stock: The Big FDA News That Has HCW Biologics Booming Today appeared first on InvestorPlace.

HCWB Stock: The Big FDA News That Has HCW Biologics Booming Today

Company cleared to proceed with first-in-human clinical trial to evaluate HCW9218, Company's lead product candidate, in refractory, advanced/metastatic pancreatic cancer

HCW Biologics Receives FDA Clearance to Proceed with Phase 1b Clinical Trial for Immunotherapeutic HCW9218 for Pancreatic Cancer

New Members Add Depth to Board with Experience in Strategic Transactions, Strategy and Commercial Planning, and Governance New Members Add Depth to Board with Experience in Strategic Transactions, Strategy and Commercial Planning, and Governance

HCW Biologics Announces Appointment of Two New Members to Board of Directors

Camber Energy

Three penny stocks that could be worth watching in the second half of October The post Making a Penny Stocks Watchlist? Don't Forget These 3 Small-Caps appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Making a Penny Stocks Watchlist? Don't Forget These 3 Small-Caps

Lead Drug Candidate Engineered Using Tissue FactOr-Based FusIon (TOBI™) Platform

HCW Biologics Showcases Scientific Paper in Molecular Therapy Highlighting Potential of HCW9218 as Novel, Bifunctional Cancer Immunotherapeutic

TOBI™ Discovery Platform Creates GMP-Scale Heteromeric Fusion Protein Complexes (HFPCs) That Solve Issues with Multi-Signal Receptor Engagement on Immune Cells

HCW Biologics' Article Published in Cancer Immunology Research Validates Novel Tissue Factor Scaffold Fusion Protein (TOBI™) Discovery Platform

MIRAMAR, Fla., Aug. 13, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), an innovative, biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2021.

HCW Biologics Reports Second Quarter Financial Results and Recent Business Highlights

MIRAMAR, Fla., July 22, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (NASDAQ:HCWB) (the "Company"), an innovative preclinical stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today announced the closing of its previously announced underwritten initial public offering of 7,000,000 shares of common stock at a public offering price of $8.00 per share for gross proceeds of $56.0 million, prior to deducting underwriting discounts, commissions, and other offering expenses. All of the shares of common stock were offered by the Company. The shares began trading on the Nasdaq Global Market on July 20, 2021, under the ticker symbol “HCWB.” In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,050,000 shares at the public offering price less the underwriting discounts and commissions.

News for HCW Biologics Stock (HCWB)